ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Summary

This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.

Timeline

Start

2007-06

Primary completion

2008-02

Completion

2008-02

Outcome

Missed primary endpoint

release “today announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint” acadia.com ↗

Drugs

Indications